PDS Biotechnology: Advancement Of PDS0101 Continues With Expansion Data (NASDAQ:PDSB)

[ad_1]

Disease X new pathogen cells

koto_feja/iStock via Getty Images

PDS Biotechnology (NASDAQ:PDSB) was able to submit an IND to begin its phase 3 VERSATILE-003 study, using PDS0101 + KEYTRUDA to treat patients with recurrent or metastatic head and neck squamous cell carcinoma [HNSCC]. I briefly spoke about

[ad_2]

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *